A daily fish oil supplement has been shown to significantly reduce serious cardiovascular events in people receiving dialysis ...

Tiziana Life Sciences ( ($TLSA) ) has shared an update. On December 17, 2025, Tiziana Life Sciences celebrated its advancements in biotechnology ...

Immense progress in gene-editing, drug discovery and conservation are just some of the reasons to be cheerful about 2025.

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer's Patients Treated with Anti-Amyloid ...

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...

UTHealth Houston, in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health), has been awarded ...

First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid ...

The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).

Here’s what most pharma professionals don’t want to hear: if you're a scientist or physician who spent your career in pharma, ...

Accenture has invested in Ryght AI, a platform provider that modernizes how clinical research is designed and executed for ...

Patient enrollment in ZYUS’ Phase 2a UTOPIA-1 trial reaches key milestone /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE ...

In an updated report, Wave Life Sciences Ltd (NASDAQ:WVE) said that enrolled patients who took 240 mg of its drug candidate, ...